Literature DB >> 18581508

Hepatopulmonary syndrome: use of extracorporeal life support for life-threatening hypoxia following liver transplantation.

Geoffrey M Fleming1, Timothy T Cornell, Theodore H Welling, John C Magee, Gail M Annich.   

Abstract

Hepatopulmonary syndrome is an uncommon complication of nonacute liver failure, and in rare cases, hypoxia may be the presenting sign of liver dysfunction. The condition, once thought to be a contraindication, is improved in most cases by transplantation. There is a significant risk of postoperative, hypoxia-related morbidity and mortality in patients with hepatopulmonary syndrome. We present a case of life-threatening hypoxia following liver transplantation for liver failure and associated hepatopulmonary syndrome, with successful management using extracorporeal membrane oxygenation.

Entities:  

Mesh:

Year:  2008        PMID: 18581508      PMCID: PMC4414403          DOI: 10.1002/lt.21477

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  24 in total

1.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Current status of paediatric heart, lung, and heart-lung transplantation.

Authors:  M Burch; P Aurora
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

3.  Reversal of cirrhosis-related pulmonary shunting in two children by orthotopic liver transplantation.

Authors:  J M Laberge; M L Brandt; P Lebecque; D Moulin; F Veykemans; K Paradis; L Pelletier; J Lacroix; H Blanchard; J de Ville de Goyet
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

4.  Expanded efficacy and indication of extracorporeal membrane oxygenation for preoperative pulmonary bleeding on pediatric cadaveric orthotopic liver transplantation.

Authors:  Shiro Fujita; Alan W Hemming; Takahisa Fujikawa; Alan I Reed; Richard J Howard; Max R Langham; David W Kays; Michael A Froelich; Fumiki Kushihata; Jota Watanabe
Journal:  Transplantation       Date:  2005-06-15       Impact factor: 4.939

5.  Hepatopulmonary syndrome in candidates for liver transplantation.

Authors:  G P Martínez; J A Barberà; J Visa; A Rimola; J C Paré; J Roca; M Navasa; J Rodés; R Rodriguez-Roisin
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

6.  Effects of hypoxemia on early postoperative course of liver transplantation in pediatric patients with intrapulmonary shunting.

Authors:  S Uemoto; Y Inomata; H Egawa; K Satomura; T Kiuchi; H Okajima; K Asonuma; K Sano; S Uyama; K Tanaka
Journal:  Transplantation       Date:  1997-02-15       Impact factor: 4.939

7.  Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications.

Authors:  H Egawa; M Kasahara; Y Inomata; S Uemoto; K Asonuma; S Fujita; T Kiuchi; M Hayashi; T Yonemura; M Yoshibayashi; Y Adachi; J A Shapiro; K Tanaka
Journal:  Transplantation       Date:  1999-03-15       Impact factor: 4.939

8.  Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation. The Cleveland Clinic experience.

Authors:  J K Stoller; P A Lange; M K Westveer; W D Carey; D Vogt; J M Henderson
Journal:  West J Med       Date:  1995-08

9.  Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Authors:  Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

10.  Orthotopic liver transplantation in children with chronic liver disease and severe hypoxemia.

Authors:  J Hobeika; D Houssin; O Bernard; D Devictor; G Grimon; Y Chapuis
Journal:  Transplantation       Date:  1994-01       Impact factor: 4.939

View more
  8 in total

Review 1.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 2.  Portopulmonary hypertension and hepatopulmonary syndrome.

Authors:  Florence Aldenkortt; Marc Aldenkortt; Laurence Caviezel; Jean Luc Waeber; Anne Weber; Eduardo Schiffer
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

Review 3.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.

Authors:  Michael J Krowka
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

4.  Extracorporeal membrane oxygenation for post-transplant hypoxaemia following very severe hepatopulmonary syndrome.

Authors:  Lakshmi Kumar; Dinesh Balakrishnan; Rekha Varghese; Sudhindran Surendran
Journal:  BMJ Case Rep       Date:  2017-11-01

5.  Extracorporeal membrane oxygenation as a bridge to liver transplantation for acute respiratory distress syndrome-induced life-threatening hypoxaemia aggravated by hepatopulmonary syndrome.

Authors:  Antoine Monsel; Hervé Mal; Hélène Brisson; Rubin Luo; Daniel Eyraud; Corinne Vézinet; Chung Hi Do; Qin Lu; Jean-Christophe Vaillant; Laurent Hannoun; Pauline Houssel; François Durand; Jean-Jacques Rouby
Journal:  Crit Care       Date:  2011-09-29       Impact factor: 9.097

Review 6.  Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome.

Authors:  D Nayyar; H S J Man; J Granton; L B Lilly; S Gupta
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

7.  Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum.

Authors:  Zakiyah Kadry; Eric Schaefer; Karen Krok; Alison Faust; Jonathan Gibson Stine; Ian Roy Schreibman; Dmitri Bezinover; Thomas Roberts Riley
Journal:  JHEP Rep       Date:  2021-08-12

8.  Annexin A1 protein regulates the expression of PMVEC cytoskeletal proteins in CBDL rat serum-induced pulmonary microvascular remodeling.

Authors:  Bin Yi; Jing Zeng; Guansong Wang; Guisheng Qian; Kaizhi Lu
Journal:  J Transl Med       Date:  2013-04-15       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.